Pharma doesn’t always need a new molecule to make billions. It needs a new story.
For years, the industry’s narrative has been simple: discover a breakthrough compound, file the patents, and ride the wave. But the modern playbook—especially for large p…
Biopharma is entering a new kind of cliff—not the one on the label, but the one in the balance sheet.
When a drug’s patent protection expires, the market doesn’t just “open.” It floods. Generics arrive faster than many commercial teams can re-plan, pri…
One-shot: How to pick the right drug patent for maximum term-extension value
In pharma, timing is everything—but so is which clock you’re trying to extend.
Drug patent term extensions (and related exclusivity add-ons) can represent real, measurable val…
One Shot: How to Pick the Right Drug Patent for Maximum Drug Patent Term Extension Value Read Post »
Drug patent litigation isn’t just about the molecule—it’s about the design choices around it.
In the last decade, “design-around” has evolved from a legal strategy into a core product-development discipline. And nowhere is that more true than in the …
Drug patent litigation isn’t just about molecules—it’s about design choices.
In pharma, “design around” sounds like a strategy. In practice, it’s a discipline: a way to translate patent language into formulation decisions, development timelines, and …
Pharma has a $300 billion question it can’t afford to misread: is it getting a patent “term restoration” or a patent “term adjustment”?
On paper, the difference sounds technical. In practice, it can determine whether a blockbuster’s exclusivity window …
Pharma has a $300B problem—and it’s not just about patents. It’s about time.
In the U.S., the patent system doesn’t merely grant exclusivity; it also tries to compensate for delays outside a drugmaker’s control. That’s where two concepts—patent term ad…
Pharma executives don’t lose in Eurasia because they “missed a filing.” They lose because they misunderstood the system.
Drug Patent Watch’s latest piece on “Drug Patents in Eurasia—What Every Pharma Executive Actually Needs to Know” lands on a truth m…
Drug Patents in Eurasia: What Every Pharma Executive Actually Needs to Know Read Post »
Pharmaceutical patent strategy is often treated like a binary choice: fight every case, or give up and move on. But the real world is messier—and more expensive.
In a recent piece from DrugPatentWatch, the “cut, keep, or cash” decision matrix reframes …
The clock is ticking—and commercial market access vendors know it.
In pharma, timing isn’t just strategy. It’s survival. Drug launches are increasingly shaped by one hard constraint: the patent clock. As exclusivity windows narrow and litigation time…
Get new actionable insights and updates from BiotechBlog
